Drug-labels.com

Picato: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Current status: Cancelled Post Market
Strength:
0.015 %, 0.05 %
Active ingredient:

Patient Medication Information: uses, side effects, how to take - Picato

ABOUT THIS MEDICATION

What the medication is used for:

Picato® is used for the topical treatment of Actinic Keratosis.

Actinic Keratosis (AK) lesions are thick, hard, scaly patches on skin that has been damaged by too much sun (UV) exposure.

What it does:

Picato® gel contains ingenol mebutate which is thought to be toxic to cells and promote a local inflammatory response.

When it should not be used:

Do not use Picato® gel if you are allergic (hypersensitive) to ingenol mebutate or any of the ingredients in the gel.

What the medicinal ingredient is:

Picato® gel contains ingenol mebutate.

What the important nonmedicinal ingredients are:

Picato® gel contains isopropyl alcohol, hydroxyethyl cellulose, citric acid monohydrate, sodium citrate, benzyl alcohol and purified water.

What dosage forms it comes in:

Picato® is a clear, colourless gel available in 2 strengths.

Picato® gel 0.015 %: Each carton contains 3 unit dose tubes

Picato® gel 0.05 %: Each carton contains 2 unit dose tubes

WARNINGS AND PRECAUTIONS

  • Do not apply the gel in, near, or around the eyes. Picato® gel is irritating to the eyes. If accidental application to the eye occurs, flush the area with plenty of water and seek medical care immediately
  • Do not apply the gel on the inside of the nostrils, on the inside of the ears, on or near the mouth and lips, or on skin outside the treatment area as defined by your doctor.
  • Do not apply Picato® 0.05% on the face or scalp, only use Picato® 0.015% on the face or scalp.
  • Make sure that the skin has healed from the other treatments or surgery before applying Picato® gel.
  • Do not use Picato® on open wounds or areas of damaged skin.
  • If Picato® gel is accidentally swallowed drink plenty of water

    • and seek medical care immediately.
    • Look out for any new scaly red patches, open sores, elevated or warty growths within the treatment area. If any of these occur, talk to your doctor.
    • Picato® gel has not been studied in patients under 18 years of age.

BEFORE you use Picato® gel talk to your doctor or pharmacist if you:

  • Are pregnant or planning to become pregnant.

  • Are breastfeeding.
  • Have had other treatments for AK.

INTERACTIONS WITH THIS MEDICATION

Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including non-prescription medicines (such as vitamins, herbal remedies, etc.). It is not known if Picato® gel and other medicines can affect each other.

PROPER USE OF THIS MEDICATION

Always use Picato® gel exactly as prescribed by your doctor and only on the area(s) of skin to be treated. Use the correct Picato® gel on the correct skin area. Do not use Picato® gel 0.05% on the face or scalp.

Usual dose:

  • For treatment of AK on the face or scalp, use one unit dose tube of 0.015% gel once daily for 3 days in a row.
  • For treatment of AK on the body, arms, hands or legs, use one unit dose tube of 0.05% gel once daily for 2 days in a row.

Instructions for use:

  • Open a new tube each time you use Picato® gel. Remove the cap from the tube just before using.
  • Squeeze the contents from one tube onto your fingertip.
  • One tube has enough gel to cover about a 25 cm2 (5 cm x 5 cm) area of skin.
  • Gently rub the gel over the affected skin area.
  • To help prevent accidental transfer of Picato® gel to your eyes or other areas of your body:

    • Wash your hands immediately after applying Picato® gel. If you are treating your hands, you should wash only the fingertip you used for applying the gel.
    • Allow the area to dry for 15 minutes.
    • Do not wash or touch the treated area yourself or allow anyone to touch the treated skin for a period of 6 hours after applying Picato® gel.
    • Do not apply Picato® gel immediately after taking a shower or less than 2 hours before bedtime.
  • After 6 hours you may wash the area with a mild soap and water.
  • Do not cover the treated skin area with a bandage or other type of dressing after you have applied Picato® gel.
  • Avoid shaving the treated skin area during treatment with
  • Picato®.

Overdose:

In case of drug overdose or accidental ingestion, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:

If you miss a dose, contact your doctor.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Side effects with Picato® include:

The most common side effects:

Local skin reactions at the treatment site. These include redness, flaking, scabbing and crusting, swelling, blister or ulcer, skin that becomes hard or thickened, and peeling skin. These reactions can start within one day of treatment and may get worse for up to one week after you have stopped using Picato®. These will usually get better within 2 weeks from when you started treatment on the face or scalp, and within 4 weeks from when you started treatment on body, arms, hands or legs. If these reactions do not improve, see your doctor.

Common side effects:

Pain, itching, skin irritation or infection at the treatment area, swelling around the eyes, and headache.

Side effects need immediate medical attention and help:

  • Serious allergic reaction (swelling of the lips or tongue, trouble breathing or wheezing, chest tightness, dizziness or passing out)
  • Stevens-Johnson syndrome (unexplained widespread skin pain, red or purple skin rash that spreads, blisters on skin and the mucous membrane of mouth, nose, eyes and genitals, shedding of skin within days after blisters form)
  • Serious chemical pinkeye and serious burn injuries to the eyes

It is possible that you may experience lightening or darkening of your skin with the use of Picato® gel. In addition, there can be scarring of the skin.

Talk to your Health Care Provider if you have questions about your treatment or side effects.

HOW TO STORE IT

Store Picato® gel in a refrigerator (2°C to 8°C).

Keep Picato® gel out of the reach of children and pets.

Do not use Picato® gel after the expiry date (EXP). Tubes should not be re-used once opened.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

--------------------------------------------------------------------------

  • Report online at www.healthcanada.gc.ca/medeffect
  • Call toll-free at 1-866-234-2345
  • Complete a Canada Vigilance Reporting Form and:

    • Fax toll-free to 1-866-678-6789, or
    • Mail to: Canada Vigilance Program

      Health Canada

      Postal Locator 0701D

      Ottawa, Ontario

      K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at:

www.leo-pharma.com/canada or by contacting the sponsor, LEO Pharma Inc., at: 1-800-668-7234. Additional information can also be found at www.picatosupport.ca.

® Registered trademark of LEO Pharma A/S used under license by LEO Pharma Inc., Thornhill, L3T 7W8

Last revised: February 20, 2020

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02400987

Revision date stated in the text: February 20, 2020

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Picato

Rx or OTC
Prescription (Rx)?
DIN 02400987, 02400995
Schedule(s) PRESCRIPTION
Active ingredient(s) Ingenol mebutate
Dosage form(s) Gel
Route(s) of administration Topical
Drug class (WHO ATC)
  1. D Dermatologicals
    1. D06 Antibiotics and chemotherapeutics for dermatological use
      1. D06B Chemotherapeutics for topical use
        1. D06BX Other chemotherapeutics
          1. D06BX02 Ingenol mebutate
Company LEO PHARMA INC
Current status Cancelled Post Market
Current status date October 14, 2020
Strengths and forms
DIN Strength Dosage form(s) Current status
02400987 0.015 % Gel Cancelled Post Market October 14, 2020
02400995 0.05 % Gel Cancelled Post Market October 14, 2020

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.